Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.

Rassi FE, Khoury HJ.

Pharmgenomics Pers Med. 2013 Aug 5;6:57-62. doi: 10.2147/PGPM.S32145. Review.

2.

Bosutinib in the management of chronic myelogenous leukemia.

Amsberg GK, Schafhausen P.

Biologics. 2013;7:115-22. doi: 10.2147/BTT.S30182. Epub 2013 May 6.

3.

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia.

Amsberg GK, Koschmieder S.

Onco Targets Ther. 2013;6:99-106. doi: 10.2147/OTT.S19901. Epub 2013 Mar 4.

4.

Bosutinib for Chronic Myeloid Leukemia.

Breccia M, Binotto G.

Rare Cancers Ther. 2015;3:35-46. Epub 2015 Aug 26. Review.

5.

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

Shen AQ, Wilson NM, Gleason SL, Khoury HJ.

Ther Adv Hematol. 2014 Feb;5(1):13-7. doi: 10.1177/2040620713510481. Review.

6.

Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Hill BG, Kota VK, Khoury HJ.

Expert Rev Anticancer Ther. 2014 Jul;14(7):765-70. doi: 10.1586/14737140.2014.924400. Epub 2014 May 30.

PMID:
24875651
7.

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.

Keller-V Amsberg G, Brümmendorf TH.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84. Review.

PMID:
23098112
8.

Bosutinib treatment for Philadelphia chromosome-positive leukemias.

Bethelmie-Bryan B, Lord K, Holloway S, Khoury HJ.

Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.

PMID:
24490604
9.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.

Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27.

PMID:
19039322
10.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C.

Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17. Erratum in: Blood. 2014 Aug 7;124(6):981.

11.

Bosutinib: a novel second-generation tyrosine kinase inhibitor.

Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH.

Recent Results Cancer Res. 2014;201:81-97. doi: 10.1007/978-3-642-54490-3_4. Review.

PMID:
24756786
12.

Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.

Stansfield L, Hughes TE, Walsh-Chocolaad TL.

Ann Pharmacother. 2013 Dec;47(12):1703-11. doi: 10.1177/1060028013503124. Review.

PMID:
24396109
13.

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Levinson NM, Boxer SG.

PLoS One. 2012;7(4):e29828. doi: 10.1371/journal.pone.0029828. Epub 2012 Apr 6.

14.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.

Keller G, Schafhausen P, Brummendorf TH.

Expert Rev Hematol. 2009 Oct;2(5):489-97. doi: 10.1586/ehm.09.42. Review.

PMID:
21083014
15.

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian HM, Brümmendorf TH.

Am J Hematol. 2014 Oct;89(10):947-53. doi: 10.1002/ajh.23788. Epub 2014 Jul 21.

16.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE.

Am J Hematol. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728. Epub 2014 Apr 28.

17.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.

18.

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

Hsyu PH, Mould DR, Upton RN, Amantea M.

Cancer Chemother Pharmacol. 2013 Jan;71(1):209-18. doi: 10.1007/s00280-012-1998-4. Epub 2012 Oct 16. Erratum in: Cancer Chemother Pharmacol. 2013 Apr;71(4):1105-6.

PMID:
23070145
19.

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Sweet K, Pinilla-Ibarz J, Zhang L.

Patient Prefer Adherence. 2014 Jul 8;8:981-6. doi: 10.2147/PPA.S53160. eCollection 2014. Review.

20.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651

Supplemental Content

Support Center